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Infection with Plasmodium falciparum and vivax cause most cases of malaria. Emerging resistance to
current antimalarial medications makes new drug development imperative. Ideally a new antimalarial
drug should treat both falciparum and vivax malaria. Because malaria parasites are purine auxotrophic,
they rely on purines imported from the host erythrocyte via Equilibrative Nucleoside Transporters
(ENTs). Thus, the purine import transporters represent a potential target for antimalarial drug devel-
opment. For falciparum parasites the primary purine transporter is the P. falciparum Equilibrative
Nucleoside Transporter Type 1 (PfENT1). Recently we identiﬁed potent PfENT1 inhibitors with nano-
molar IC50 values using a robust, yeast-based high throughput screening assay. In the current work we
characterized the Plasmodium vivax ENT1 (PvENT1) homologue and its sensitivity to the PfENT1 in-
hibitors. We expressed a yeast codon-optimized PvENT1 gene in Saccharomyces cerevisiae. PvENT1-
expressing yeast imported both purines ([3H]adenosine) and pyrimidines ([3H]uridine), whereas wild
type (fui1D) yeast did not. Based on radiolabel substrate uptake inhibition experiments, inosine had the
lowest IC50 (3.8 mM), compared to guanosine (14.9 mM) and adenosine (142 mM). For pyrimidines,
thymidine had an IC50 of 183 mM (vs. cytidine and uridine; mM range). IC50 values were higher for
nucleobases compared to the corresponding nucleosides; hypoxanthine had a 25-fold higher IC50 than
inosine. The archetypal human ENT1 inhibitor 4-nitrobenzylthioinosine (NBMPR) had no effect on
PvENT1, whereas dipyridamole inhibited PvENT1, albeit with a 40 mM IC50, a 1000-fold less sensitive than
human ENT1 (hENT1). The PfENT1 inhibitors blocked transport activity of PvENT1 and the ﬁve known
naturally occurring non-synonymous single nucleotide polymorphisms (SNPs) with similar IC50 values.
Thus, the PfENT1 inhibitors also target PvENT1. This implies that development of novel antimalarial
drugs that target both falciparum and vivax ENT1 may be feasible.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
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Ltd on behalf of Australian Society fAccording to the World Health Organization (WHO), in 2014
approximately 3.4 billion people were at risk for malaria infection
(World Health Organization, 2014). Over 200 million clinical cases
of malaria resulted in ~600,000 deaths. Most deaths occurred in
sub-Saharan Africa in young children and pregnant women (Snow
et al., 2005; World Health Organization, 2014). Malaria is caused by
infection with single-cell protozoan parasites from the genus
Plasmodium. Five Plasmodium species infect humans (Plasmodium
falciparum, vivax, malariae, ovale, and knowlesi). Ninety percent of
clinical cases are due to infection with either P. falciparum or Plas-
modium vivax (World Health Organization, 2014). P. falciparum is
associated with the highest mortality (~80% of all malaria-related
deaths) but P. vivax infection is prevalent and associated with
high morbidity (Rogerson and Carter, 2008; Anstey et al., 2009).or Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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areas is signiﬁcant, especially in tropical regions. Thus, new anti-
malarial drugs should target both species.
The development of resistance to antimalarial drugs has been a
recurring problem. Chloroquine (CQ) was the mainstay of antima-
larial chemotherapy until CQ resistance developed worldwide
(Wellems and Plowe, 2001). In 2006, the WHO recommended
Artemisinin-based Combination Therapies (ACT) as ﬁrst-line
treatment for P. falciparum infection. Unfortunately, resistance to
current ACT regimens is expanding in Southeast Asia (Dondorp
et al., 2011; Ariey et al., 2014; Hastings et al., 2015; Straimer et al.,
2015). The fact that resistance to a three day ACT treatment
course emerged in as little as a decade after the large scale intro-
duction of ACTs as ﬁrst line therapy underscores the importance of
identifying new drug targets that take advantage of weaknesses in
Plasmodium biology.
One potential target for the development of novel antimalarial
drugs is the purine salvage pathway (Downie et al., 2008; Cassera
et al., 2011; Frame et al., 2015a). Similar to other protozoa, Plas-
modium species can perform de novo pyrimidine synthesis but are
incapable of de novo purine synthesis (Manandhar and Van Dyke,
1975; Gero and O'Sullivan, 1990; Downie et al., 2008; Frame
et al., 2015a). Therefore, Plasmodium parasites must import pu-
rines from the host cytoplasm. Imported purines are processed via
the purine salvage pathway enzymes to form the purines required
for RNA synthesis, DNA replication, and metabolism. Hence, the
purine import and processing pathways are potential targets for
antimalarial drug development (Downie et al., 2008; Ducati et al.,
2013; Frame et al., 2015a).
Plasmodium parasites use equilibrative nucleoside transporters
(ENT) to import purines (Landfear et al., 2004; Downie et al., 2008).
Genomic sequence analysis of P. falciparum (3D7) and P. vivax (Sal I)
(www.PlasmoDB.org) shows that both species possess four puta-
tive ENT homologues: PfENT1-4 and PvENT1-4 (Martin et al., 2005;
Kirk and Lehane, 2014). P. falciparum ENTs have been studied more
extensively. Multiple genetic, biochemical, and functional experi-
ments show that PfENT1 is the principle route for purine uptake
into the P. falciparum parasites. PfENT1 is localized to the parasite
plasma membrane and transports both purine and pyrimidine
substrates (Carter et al., 2000a; Parker et al., 2000; Rager et al.,
2001; Riegelhaupt et al., 2010a). Genetic knockout of the PfENT1
gene (pfent1D) is lethal if the parasites are grown in concentrations
of purines present in human blood, <10 mM (Traut, 1994; El Bissati
et al., 2006; El Bissati et al., 2008; Frame et al., 2015b). However,
PfENT1-knockout parasites survive when grown in culture with
supra-physiologic purine concentrations (>100 mM) (El Bissati
et al., 2006; El Bissati et al., 2008; Frame et al., 2015b). Thus, a
secondary low afﬁnity and/or low capacity purine transport
pathway must be present, at least in the pfent1D parasites. The
molecular basis for this secondary purine uptake pathway is un-
known but may involve the AMP uptake pathway (Cassera et al.,
2008) or possibly, PfENT4 (Frame et al., 2012).
To test whether chemical inhibition of PfENT1would be lethal to
P. falciparum parasites, we identiﬁed PfENT1 inhibitors using a
yeast-based, high-throughput screen (HTS) (Frame et al., 2015b).
We screened 64,500 compounds and identiﬁed 171 hits. Nine of the
highest activity compounds that represent six distinct chemical
scaffolds were characterized in depth. They blocked [3H]adenosine
uptake into PfENT1-expressing yeast and into erythrocyte-free
trophozoite stage parasites with 5e50 nM IC50 values and killed
chloroquine-sensitive and -resistant P. falciparum parasites with
5e50 mM IC50 values (Frame et al., 2015b). These results provide
strong support for the hypothesis that inhibition of purine uptake is
a potential target for the development of novel antimalarial drugs.
Because of the extensive geographic overlap between vivax andfalciparum malaria, an effective antimalarial drug should treat
infection by both parasites. In the current work, we sought to
characterize P. vivax ENT1 (PvENT1) functionally and determine
whether the PfENT1 inhibitors also inhibit PvENT1. Based on its
genomic sequence, PvENT1 is a 47.3 kDa, 416 amino acid protein.
PvENT1 shares ~75% amino acid sequence identity with PfENT1.
However, unlike its P. falciparum homologue, the pvent1 gene is
only moderately AT rich (57%; vs. 72% pfent1). Although no crystal
structures are available for any known ENTs, glycosylation scanning
and modeling algorithms support an 11-transmembrane segment
topology with a cytoplasmic N-terminus and an extracellular C-
terminus (Sundaram et al., 2001; Valdes et al., 2009). Hydropathy
plots suggest that PvENT1 has a similar transmembrane topology to
PfENT1. In the current work, we expressed PvENT1 in Saccharo-
myces cerevisiae. We showed that a similar group of purine and
pyrimidine nucleobases and nucleosides competed with radioac-
tive uridine or adenosine uptake into PvENT1-expressing yeast, but
the measured IC50s were distinct from those previously reported
for PfENT1-expressing yeast (Frame et al., 2015b). We determined
the sensitivity of PvENT1 to the recently identiﬁed PfENT1 in-
hibitors. All nine PfENT1 inhibitors block PvENT1 with similar ef-
ﬁcacy. Furthermore, the ﬁve known PvENT1 non-synonymous
single nucleotide polymorphisms (SNP) have minimal impact on
inhibitor potency.
2. Materials and methods
2.1. Purine auxotrophic yeast (ade2D)
All genetically modiﬁed yeast were created using the
S. cerevisiae BY4741strain that also had a deletion of the FUI1 gene
(MATa; his3D 1; leu2D 0; met15D 0; ura3D 0; fui1D::KanMX4)
(Winzeler et al., 1999). To disrupt de novo purine synthesis in
S. cerevisiae, we replaced the yeast ADE2 gene (Chr. 15;
phosphoribosyl-aminoimidazole carboxylase) with the hphNT1
(hygromycin B phosphotransferase) selectable marker using ho-
mologous recombination. Brieﬂy, using two-step PCR, we created
45 nt 50 and 30 ade2 homology arms ﬂanking the hphNT1 gene
(which was ampliﬁed from the pFA6a-hphNT1 plasmid; gift from
Dr. Ian Willis). The following sets of primers were used: 1st-stepF:
50GACAAAACAATCAAGTATGCGTACGCTGCAGGTCGACGGATCCCC-
G-30, 1st stepR: 50-GTATATCAATAAACTTATA-
TATTAATCGATGAATTCGAGCTCG-30; 2nd-stepF: 50-
AACAATCAAGAAAAACAAGAAAATCGGACAAAACAATCAAGTATG-30,
2nd stepR: 50-TTATAATTATTTGCTGTACAAGTATATCAATAAACTTA-
TATATTA-30. The underlined portion corresponds to the sequence of
yeast chromosomal DNA ﬂanking the ADE2 gene. Each 100 mL PCR
reaction contained 50 ng DNA,1x PfuUltraII Reaction Buffer, 250 mM
of each dNTP (dATP, dCTP, dGTP, dTTP), 0.2 mM of each primer (F/R),
2% (v/v) PfuUltraII Fusion HS DNA Polymerase (Agilent). The PCR
conditions were: 1 cycled95 C (2 min); 26 cyclesd95 C (30 s),
60 C (30 s), 72 C (30 s); 1 cycled72 C (2 min), 4 C (hold). The
PCR product was veriﬁed using ethidium bromide agarose gel
electrophoresis, excised, and column puriﬁed. The amplicon was
transformed into yeast (see below) and plated on YPD þ 500 mM
hygromycin B selection plates at 30 C. The resulting yeast strain
was MATa; his3D 1; leu2D 0; met15D 0; ura3D 0; fui1D::KanMX4,
ade2D::hphNT1. Disruption of the ade2 gene was conﬁrmed by PCR.
The purine auxotrophic yeast was pigmented red and displayed a
retarded growth phenotype under purine starved conditions
(Kokina et al., 2014). Single colonies of the purine auxotrophic yeast
were picked and expanded for transformation with the pCM189
constructs.
The purine auxotrophic yeast strainwith the ADE2 gene deletion
(ade2D::hphNT1) was used in all experiments in this paper and was
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ing the PvENT1 gene or an empty vector (EV) lacking the PvENT1
gene. All subsequent references to “yeast” in the Results section
refer to this purine auxotrophic strain.
2.2. PvENT1 DNA plasmid constructs
We synthesized a yeast codon-optimized version of the PvENT1
gene (Gene Designer® DNA2.0) based on the inferred amino acid
sequence of PVX_083260 gene sequence in PlasmoDB (http://www.
plasmodb.org/plasmo/) (DNA sequence available on request). The
construct contained a 50 BamHI restriction site, the 1251 bp codon-
optimized gene, and a 30 EcoRI restriction site. The construct was
sub-cloned into the yeast pCM189 plasmid (Gari et al., 1997) using
BamHI/EcoRI restriction enzymes and T4 DNA ligase. The endoge-
nous EcoRI site upstream of the tetracycline regulatable element in
pCM189 was deleted using site-directed mutagenesis prior to
cloning steps. The plasmid is a low copy number, tetracycline reg-
ulatable yeast expression vector; selectable markers include an
ampicillin resistance (AmpR; for maintenance in E. coli) and the
orotodine 50-phosphate decarboxylase (Ura3; for maintenance in
S. cerevisiae). A strong synthetic promoter based on the CYC1 pro-
moter drives PvENT1 expression. The ﬁnal construct generated was
pCM189tetOff-PvENT1 (Gari et al., 1997). The empty vector (EV)
construct pCM189-EV lacked only the transporter gene. All se-
quences were veriﬁed by DNA sequencing (Genewiz, Inc.).
PvENT1 SNP mutant constructs were generated using the
QuikChange site-directed mutagenesis kit (Agilent Technologies)
according to the manufacturer's recommendations. Point muta-
tions were veriﬁed by DNA sequencing.
2.3. Yeast transformation with PCR amplicon and pCM189
constructs
Yeast was transformed with plasmid or PCR DNA using the
standard lithium-acetate/DMSO (8% v/v) method (Hill et al., 1991).
For each transformation 10 mL of yeast culture was grown over-
night in YPDmedia until the cell density reached ~2 107 cells/mL.
The culturewas pelleted at 3500 g, 5min (room temperature; RT)
and the yeast pellet was washed once with cold lithium acetate
buffer (LiOAc: 100 mM LiOAc, 10 mM Tris pH 8; using 2 PBS vol/
culture vol). The ﬁnal pellet was resuspended with 100 mL of LiOAc
to which 10 mL of salmon-sperm DNA (2 mg/mL) and 0.5e1 mg of
DNA (PCR or construct) was added. The solution was incubated at
RT for 5 min 280 mL of 50% (w/v) PEG (polyethylene glycol 3350)
was added. The PEG-LiOAc suspension was incubated at 30 C for
45 min. DMSO was added to the mixture and the sample was heat
shocked at 42 C for 15 min. Transformed samples were pelleted at
16,300  g, 30 s (RT) and resuspended in appropriate media before
being transferred onto selection plates. For the creation of
ade2D::hphNT1 yeast, the ﬁnal pellet was ﬁrst resuspended in
10 mL YPD, allowed to recover for 3 h, pelleted again, and resus-
pended into a plating volume containing 500 mMhygromycin B. The
ﬁnal strains used in experiments had the following genotype:
MATa; his3D 1; leu2D 0; met15D 0; ura3D 0; fui1D::KanMX4,
ade2D::hphNT1 containing either pCM189-EV or pCM189-PvENT1
constructs.
2.4. Yeast growth media and determination of cell density
Yeast cells were grown in YPD media: 1% (w/v) yeast extract, 2%
(w/v) peptone, and 2% (w/v) glucose. Purine auxotrophic yeast were
maintained in synthetic deﬁned media (SDM) containing 2% (w/v)
dextrose, 0.5% (w/v) ammonium sulfate, 0.17% (w/v) yeast nitrogen
base (US Biologicals, #Y2030), 0.02% (w/v) nutritional dropout mix(US Biologicals, cat# D9542; lacking uracil, adenine, histidine, and
tryptophan), 40 mg/L tryptophan, and 40 mg/L histidine. Supple-
mental adenine (300 mM) or adenosine (1 mM) was added for
culture maintenance of the EV and PvENT1 expressing yeast,
respectively. Solid growth media contained the same SDM formu-
lation supplemented with either 1 mM adenine or 10 mM adeno-
sine in 2% (w/v) agar.
Yeast cell density was determined spectrophotometrically
(Biorad Benchmark Plus) from 200 mL samples in 96-well clear, ﬂat-
bottom plates (Corning, #3596). OD600 ¼ 0.018 correlated to
~2  106 cells/mL using our experimental conditions.
2.5. Yeast growth and bioscreen assays
Purine auxotrophic yeast growthwas assessed on both solid and
liquid media where adenine or adenosine was the sole purine
source. Brieﬂy, the EV- and PvENT1-expressing yeast were grown in
SDM-adenine media to mid-log phase, harvested at 3400  g for
5 min (RT), and washed three times in sterile water. The ﬁnal yeast
cell pellet was diluted to 4  106 cells/mL in water. 96-well TC-
treated plates were preloaded with 100 mL of purine serially
diluted in 2 SDM lacking purine. 100 mL of cells were added to the
plates and resuspended three times. The cells were incubated at
30 C and evaluated for growth (OD600) after 17e21 h. Biological
replicates (n  4) were done on different days. For growth on solid
media, yeast were grown to a density of 106 cells/mL, serially
diluted inwater (1:5), inoculated onto SDM-agar plates (3000 cells/
spot) and incubated at 30 C for 2e3 days.
Bioscreen growth curve analysis for PvENT1 WT and SNP mu-
tants was done using a Bioscreen C machine (Growth Curves USA,
Piscataway, NJ). Brieﬂy, cultures were grown in the appropriate
yeast media to mid-log phase, washed as previously noted, and
then diluted to ~2  106 cells/mL (OD600 ¼ 0.018) either in 1 mM
adenine or 10 mM adenosine media. Three aliquots of 150 mL cul-
ture (per strain/per condition) were added to a 100-well plate.
Growth at 30 C was monitored every 15 min at OD600 for 72 h.
2.6. Inhibition of yeast growth with small molecule compounds
We evaluated the viability of purine auxotrophic yeast grown in
the presence of various inhibitors. Brieﬂy, 80 mL of exponentially
growing PfENT1-expressing yeast (~400,000 cells) were added to
each well of a 384-well microplate (black, clear/ﬂat-bottom, poly-
styrene; Corning #3712). The cells were grown in 1 mM adenosi-
nedthis concentration was picked based on growth that allowed
maximum signal detection without saturating the culture/machine
detection. Compound was serially diluted 3- or 4- fold in DMSO,
and 0.8 mL was added to each well and resuspended three times.
The ﬁnal DMSO concentration was ~1% (v/v). The plates were
incubated at 30 C for 15e17 h. Growth was evaluated at OD600,
values were normalized to maximum growth with DMSO only and
maximum death values for each compound. The normalized data
was ﬁt to a variable slope concentration-response model with no
constraints to determine the concentration that gave half-maximal
growth inhibition (IC50) using Prism 6.02 software (GraphPad).
Biological replicates (n  4) were done on different days.
2.7. Radiolabel uptake time course experiments
PvENT1-expressing yeast were grown to mid-log phase in
SDM þ1 mM adenosine overnight at 30 C. Cells were harvested by
centrifugation at 3500 g for 1 min, RT. Cells were washed three
times in yeast PBS (150 mM NaCl, 10 mM KH2PO4, 40 mM K2HPO4,
11 mM glucose, pH 7.4). The yeast pellet was resuspended in PBS to
a ﬁnal concentration of 2  108 cells/mL. 96-well microplate wells
Fig. 1. Function of PvENT1 in purine auxotrophic yeast. (A) The growth of purine
auxotrophic yeast transformed with either empty vector (EV) or PvENT1 depends on
the media concentration of adenine (Ade, empty symbols) or adenosine (Ado, ﬁlled
symbols) when present as the sole purine source. Data points represent the mean ± SD
of 3 technical replicates. EC50 values indicated in the text were measured from n  3
independent biological replicates. (B and C) PvENT1-mediated uptake of (B) 50 nM [3H]
adenosine or (C) 250 nM [3H]uridine in purine auxotrophic yeast transformed with
either empty vector or PvENT1. Data points in (B) and (C) represent counts
(mean ± SD) over the course of 30 min from n  3 independent experiments.
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osine; 35 Ci/mmol) or 500 nM [3H]uridine ([2,8-3H]uridine; 8.5 Ci/
mmol). All radiolabels were purchased fromMoravek Biochemicals.
100 mL of yeast cell suspension was added to the radiolabels at the
appropriate times to generate the time-course: 0, 0.5, 1, 2.5, 5, 10,
15, 20, 30, 45, and 60min. At the conclusion of the experiment, cells
were harvested onto glass ﬁber ﬁltermats (Filtermat A, GF/C; Perkin
Elmer) using a TomTec 96-well cell harvester system (#96-3-469).
Filtermats were dried, sealed in plastic bags containing Betaplate
Scint LSC ﬂuid (Perkin Elmer). Samples were counted using a
microplate scintillation counter (1450 MicroBeta TriLux, Perkin
Elmer). Total counts are represented as CPM/106 cells (mean ± SD)
from n  3 independent experiments. The data was ﬁt using a
linear-regression model with no constraints (Prism 6.02).
2.8. Radiolabel-uptake inhibition by purines and pyrimidines
PvENT1-expressing yeast were grown and prepared as
described above. To measure the concentration dependent inhibi-
tion of radiolabel uptake, 96-well plates were preloaded with 50 mL
of 200 nM [3H]adenosine for pyrimidines or 1 mM [3H]uridine for
purines in PBS. 50 mL of purine or pyrimidine (serially diluted 3- or
4- fold in buffer) was added to each well and resuspended. 100 mL
yeast (2  108 cells/mL) were added to each well and incubated at
RT for 15 min. At the end of each experiment, cells were harvested
and radioactivity was counted. Biological replicates (n  3) were
done on different days.
2.9. [3H]adenosine uptake inhibition by compounds
Compounds identiﬁed as PfENT1 inhibitors were purchased
from Chembridge. Validation of purchased compounds by mass
spectrometry and NMR were published previously (Frame et al.,
2015b). To measure the concentration dependence of compound
inhibition of [3H]adenosine uptake, 96-well plates were preloaded
with 100 mL of 100 nM [3H]adenosine in PBS. 0.5 mL of compound
(serially diluted 3- or 4- fold in DMSO, as described above) was
added to eachwell and resuspended.100 mL yeast (2 108 cells/mL)
were added to each well and incubated at RT for 15 min. At the end
of each experiment, cells were harvested and radioactivity was
counted. Biological replicates (n  3) were done on different days.
3. Results
3.1. Expression of P. vivax ENT1 in yeast
The amino acid sequences of PvENT1 and PfENT1 are 75%
identical. Since PfENT1 is a low afﬁnity, broad-spectrum trans-
porter of nucleosides and nucleobases, we hypothesized that
PvENT1 would also recognize and transport these substrates. To
study PvENT1, we expressed PvENT1 in S. cerevisiae yeast. We used
a yeast codon-optimized version of the PvENT1 gene because
species-speciﬁc differences in codon usage can affect gene
expression levels (codon usage bias) (Hershberg and Petrov, 2009;
Downie et al., 2010; Frame et al., 2012, 2015b). We used purine
auxotrophic S. cerevisiae generated by deletion of the ADE2 gene, a
critical enzyme in the yeast's de novo purine synthetic pathway.
Purine auxotrophic ade2D yeast grow poorly when purine starved
and display a characteristic red color phenotype (Dorfman, 1969;
Kokina et al., 2014). Adenine can enter ade2D yeast cells via the
endogenous FCY2 nucleobase transporter and rescue growth
(Schmidt et al., 1984). Yeast do not encode an endogenous adeno-
sine transporter. Thus, growth of the purine auxotrophic yeast with
adenosine as the sole purine source can only occur if adenosine can
enter the cell through the PvENT1 transporter.Yeast transformed with either an empty vector (EV) or PvENT1
construct displayed similar concentration-dependent growth in
liquid culture media containing adenine as the sole purine source
(Fig. 1A) (EC50: 39 ± 2 mM EV vs. 27 ± 2 mM PvENT1). In contrast,
PvENT1-expressing yeast grew in adenosine media (growth EC50:
394 ± 85 mM), while EV yeast failed to grow (Fig. 1A). Similar
growth phenotypes were observed for the yeast cells grown on
solid media (data not shown). Growth rescue with adenosine as the
Fig. 2. Inhibition of uptake of [3H]adenosine or [3H]uridine into PvENT1-expressing
yeast in the presence of selected purines and pyrimidines. (A) Uptake inhibition of
radiolabel by select purine substrates after 15 min incubation period. (Urd) represents
uptake of 250 nM [3H]uridine and (Ado) represents the same experiment done with
50 nM [3H]adenosine. (B) Uptake inhibition of 50 nM [3H]adenosine by select py-
rimidine substrates in the uracil series after 15 min incubation. Single experiment
traces are shown in (A) and (B). Inhibition of radiolabel uptake by purine/pyrimidine
substrates were ﬁt to a non-linear regression model, unless there was no observable
effect (e.g., UMP).
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functional PvENT1 protein. We assume that the PvENT1 protein
trafﬁcked to the yeast plasma membrane but we did not explicitly
demonstrate this.
Next, we examined whether PvENT1-expressing yeast could
transport two radiolabeled substrates, adenosine and uridine.
PvENT1-expressing yeast cells displayed time-dependent, linear
accumulation of both [3H]adenosine and [3H]uridine (Fig. 1B and C,
circles). As expected, EV transformed yeast not expressing PvENT1
did not accumulate either [3H]adenosine or [3H]uridine (Fig. 1B and
C, squares). Since yeast lack an endogenous adenosine transporter
and the endogenous FUI1 uridine transporter was deleted (fui1D),
uptake of both radiolabeled substrates is only possible through
PvENT1. The uptake of both purines and pyrimidines is consistent
with the broad substrate speciﬁcity of the transporter.
3.2. PvENT1 mediated transport of purines and pyrimidines
We investigated whether other purines and pyrimidines could
affect PvENT1-mediated uptake of radiolabeled adenosine or uri-
dine. To avoid the potential for competition between the test sub-
stance and the radiolabeled substrate at cytoplasmic metabolic
enzymes (Kirk et al., 2009; Riegelhaupt et al., 2010a), we used the
inhibition of [3H]uridine uptake to characterize purine uptake and
inhibition of [3H]adenosine to characterize pyrimidine uptake.
Thus, the radiolabel is metabolized by different cytoplasmic en-
zymes than the competing cold substance. The only potential site of
competition between the test substance and radioactive substrate
is at the transporter. For these experiments, we assume that inhi-
bition of radiolabel uptake is due to the competitive transport of the
purine or pyrimidine test substance by the transporter. Unfortu-
nately, due to ﬁnancial constraints we did not have radiolabeled
versions of all of the test substances to demonstrate that they were
all transported into the yeast via PvENT1.
We quantiﬁed the observed effects as the IC50 of the test sub-
stance to inhibit the radiolabeled substrate uptake into the yeast. It
should be noted that for these experiments, the ratio of the tritiated
substrate concentration used in the uptake competition experi-
ments to the test substance Km was between 103 and 104. Thus,
by the ChengePrusoff equation the IC50 z Ki, where Ki is the in-
hibition constant of the test substance for the transporter (Cheng
and Prusoff, 1973).
We evaluated 11 purines for their ability to inhibit [3H]uridine
uptake into PvENT1-expressing yeast. These included nucleobases,
nucleosides, and nucleotides. Experiments were conducted at
15 min, which was within the linear phase of radiolabel uptake
(Fig. 1C). Fig. 2A illustrates the experimental data for determination
of IC50 values for the inhibition of radiolabel uptake by the purines
inosine, hypoxanthine and xanthine. In this case, similar results
were obtained whether the radiolabel substrate was a purine
(adenosine) or a pyrimidine (uridine) implying that in both cases
the inhibition of radiolabel uptake is due to competition at the
PvENT1 transporter and not at a cytoplasmic metabolic enzyme.
IC50 values for all purines tested are shown in Table 1. The nucle-
osides inosine and guanosine had the lowest IC50 values, in the low
mM range, while their nucleobases were 50 and 300 times higher,
respectively (Table 1). Adenosine had an IC50 value of 142 mMwhile
the IC50 for its nucleobase adenine was one order of magnitude
higher (Table 1).
Similarly, we evaluated 11 pyrimidines for their ability to inhibit
the uptake of 50 nM [3H]adenosine. Fig. 2B illustrates the experi-
mental data for determination of IC50 values for the inhibition of
[3H]adenosine uptake into PvENT1-expressing yeast bymembers of
the uracil series of pyrimidines. IC50 values for all pyrimidines
tested are shown in Table 1. The nucleoside thymidine had thelowest IC50 of all pyrimidines tested (183 mM) followed by its
nucleobase thymine (564 mM) (Table 1). The nucleobase cytosine
caused slight inhibition of [3H]adenosine uptake while the
remaining members of the family had negligible effects. The uracil
family of pyrimidines had IC50 values in the lowmM range (Fig. 2B,
Table 1). 5-Fluorouridine (5-FUrd), a toxic uridine analog, had an
IC50 value of 1.7 mM.
None of the purine or pyrimidine nucleotides tested inhibited
the uptake of [3H]adenosine or [3H]uridine. This implies that nu-
cleotides are not substrates for PvENT1. Overall, our data show that
PvENT1 recognizes both purine and pyrimidine substrates in the
form of nucleosides and nucleobases.
Substitution of choline chloride for NaCl in the [3H]adenosine
uptake media had a minimal impact on 15 min [3H]adenosine up-
take (data not shown). This indicated that purine uptake was not
Naþ coupled in PvENT1.3.3. Effect of hENT1 inhibitors and cytotoxic purines on PvENT1-
mediated purine uptake
Mammalian ENTs are categorized based on their sensitivity to
the inhibitor NBMPR (Grifﬁths et al., 1997; Baldwin et al., 2004).
Human hENT1 is inhibited by sub-nanomolar NBMPR concentra-
tions, whereas hENT2 requires mM-mM concentrations for com-
plete inhibition. Similarly, hENT1 is inhibited by the coronary
vasodilator dipyridamole in the 5e20 nM concentration range
(Grifﬁths et al., 1997; Baldwin et al., 2004). NBMPR did not inhibit
[3H]adenosine uptake into PvENT1-expressing yeast at concentra-
tions up to 20 mM. Dipyridamole inhibited the transporter with an
IC50 ~ 40 mM, about three orders of magnitude higher than the IC50
Table 1
IC50 values for inhibition of [3H]Uridine uptake by purines and [3H]Adenosine uptake by pyrimidines. Inhibition of uptake of [3H]uridine or [3H]adenosine by varying con-
centrations of purine/pyrimidine substrates evaluated in PvENT1-expressing yeast. IC50 values were obtained from concentration-response experiments similar to that
presented in Fig. 2. Results are expressed as mean ± SD (mM) from n  3 independent experiments. Values in parenthesis are IC50 values determined using [3H]adenosine for
purines or [3H]uridine for pyrimidines, (Urd¼ 250 nM [3H]uridine; Ado¼ 50 nM [3H]adenosine). NE signiﬁes no observable effect on uptake of radiolabel at the concentrations
tested.
Purine IC50 for inhibition of [3H]Uridine by indicated purine (mM) Pyrimidine IC50 for inhibition of [3H]Adenosine by indicated pyrimidine (mM)
Adenine 1430 ± 736 (278 ± 62 Ado) Thymine 564 ± 145
Adenosine 142 ± 34 (74 ± 8 Ado) Thymidine 183 ± 53 (299 ± 77 Urd)
AMP NE Uracil 3390 ± 1170
Hypoxanthine 99 ± 30 (81 ± 13 Ado) Uridine 1730 ± 809
Inosine 3.8 ± 1.4 (2.7 ± 0.7 Ado) 5-Fluorouridine (5-
FUrd)
1770 ± 302
Xanthine 2550 ± 189 UMP NE
Xanthosine 4310 ± 2870 Cytosine 6140 ± 1030
Guanine 6340 ± 2950 Cytidine NE
Guanosine 14.9 ± 1.4 2-deoxycytidine NE
2- deoxyguanosine 20.5 ± 4.8 CMP
NE
GMP NE Orotic acid NE
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To explore determinants of purine recognition, we also exam-
ined the ability of two purine analogs to inhibit uptake of [3H]uri-
dine. The immunosuppressive drug 6-mercaptopurine (6-MP) had
an IC50 value of 160 mM. Surprisingly, tubercidin, a 7-deaza-aden-
osine derivative, failed to inhibit [3H]adenosine uptake (Table 2).
Tubercidin is transported by PfENT1 (Riegelhaupt et al., 2010a). This
suggests that the adenosine N7 position, which is absent in
tubercidin but present in adenosine, is an important structural
determinant for substrate recognition by PvENT1.3.4. Effect of small molecule PfENT1 inhibitors on PvENT1
Using a yeast-based high throughput screen (HTS), we recently
identiﬁed small molecule inhibitors of PfENT1 (Frame et al., 2015b).
Of the 171 hits identiﬁed, we validated the efﬁcacy of nine of the
highest activity compounds, representing six different chemotypes
(Fig. 3A) using a series of yeast- and parasite-based assays. In the
current work, we explored the ability of these nine inhibitors to
block PvENT1 using two different assays: 1) inhibition of [3H]
adenosine uptake into PvENT1-expressing yeast, and 2) inhibition
of the growth of PvENT1-expressing purine auxotrophic yeast with
adenosine as the sole purine source. All nine compounds produced
concentration-dependent inhibition of [3H]adenosine uptake with
IC50 values in the 2e40 nM range (Fig. 3B, Table 3). We assume that
these compounds that inhibit radiolabeled substrate uptake in the
nanomolar concentration range were blocking the transporter and
were not transported. However, we do not have experimental ev-
idence to support this assumption (Frame et al., 2015b). For com-
parison purposes, Table 3 includes the IC50 values obtained in the
comparable experiment with PfENT1-expressing yeast (Frame
et al., 2015b). The IC50 values for inhibition of [3H]adenosine up-
take by PvENT1-and PfENT1-expressing yeast are within a factor of
ﬁve of each other. Because the compounds have similar efﬁcacy in
the yeast based inhibition of [3H]adenosine uptake assays with
PfENT1 and PvENT1 and all nine compounds inhibited P. falciparum
proliferation in culture (Frame et al., 2015b), we hypothesize that
they will also inhibit P. vivax proliferation. However, due to the
difﬁculty of growing P. vivax in culturewe cannot currently test this.
Furthermore, all nine compounds inhibited the growth of
PvENT1-expressing purine auxotrophic yeast with adenosine as the
sole purine source in a concentration-dependent manner with IC50
values ranging from 60 nM to 1.1 mM (Table 3). A linear regression
ﬁt between the IC50 values in the two assays had a slope ¼ 30 (95%
conﬁdence interval ¼ 23 to 38; R2 ¼ 0.93). Thus, on average, thecompound IC50 values were ~30-fold higher in the growth assay
compared to the radiolabel uptake experiments (Table 3).3.5. Effect of PvENT1 non-synonymous SNPs on purine IC50 values
and sensitivity to inhibitors
The substrate and inhibitor proﬁles described above are for the
PvENT1 amino acid sequence encoded by the gene from the El
Salvador I isolate (Carlton et al., 2008). To date, genomic sequencing
of 170 P. vivax ﬁeld isolates has identiﬁed six unique non-
synonymous SNPs in the PvENT1 gene (PVX_083260). Two of the
SNPs, M99I and Q367K, always appear together (http://www.
plasmodb.org/plasmo/showRecord.do?name¼GeneRecordClasses.
GeneRecordClass&project_id¼PlasmoDB&source_id¼PVX_
083260, accessed 6/30/15). The SNPs, strain and protein locations
are: D23E (Thailand VKTS-52, N-terminus), M99I/Q367K double
mutant (Brazil strain; TM 3 and TM10-11 loop), Q178K
(Columbia_30103103280, TM5-6 loop), L188M (PNG58 and others,
TM6), and N329S (N. Korea strain; TM 9). We evaluated the func-
tional signiﬁcance of the PvENT1 polymorphisms using the yeast
expression system.
Yeast expressing WT and each of the SNP mutant PvENT1s grew
at a similar rate with adenine as the sole purine source (Fig. 4A left
panel and B). This was expected because the yeast express an
endogenous adenine transporter.With adenosine as the sole purine
source, the M99I/Q367K double mutant PvENT1-expressing yeast
grew at rates comparable to WT (Fig. 4A right panel and C). The
D23E, Q178K, and L188M mutants also had comparable growth
rates (data not shown). This implied that these yeast all expressed
PvENT1 to a similar extent and with similar transport capacity. The
Q178K and L188M mutations increased the hypoxanthine IC50
values (Table 4). D23E, Q178K and L188M increased the inosine IC50
values by 6- to 26-fold. In contrast, none of the adenosine IC50
values were signiﬁcantly different than WT, although the Q178K
IC50 value was 3 times higher (Table 4).
The growth behavior of yeast expressing the N329S mutation
was distinctly different from WT and the other SNPs. The N329S
yeast grew on adenine as the sole purine source implying that the
purine salvage pathway was intact. In contrast, with adenosine as
the sole purine source, N329S-PvENT1-expressing yeast behaved
similar to the EV-transformed yeastdthe growth rate was minimal
even in the presence of 10 mM adenosine (Fig. 4C). This phenotype
was observed with N329S-PvENT1-expressing yeast from several
independently transformed colonies and from two independent
transformations. However, if the N329S-expressing yeast were
Table 2
IC50 Values for inhibition of [3H]Adenosine uptake by human hENT1 inhibitors and cytotoxic purine derivatives. Effect of hENT1 in-
hibitors (NBMPR, nitrobenzylthioinosine; dipyridamole) and toxic purine analogs, 6-mercaptopurine and tubercidin (7-deaza-adeno-
sine) on uptake inhibition of 50 nM [3H]adenosine into PvENT1-expressing yeast. Inhibition was evaluated over a range of
concentrations up to 20 mM. IC50 values are represented as the mean ± SD from n ¼ 3 separate experiments. NE signiﬁes no observable
effect.
Compound [3H]Adenosine uptake inhibition IC50 (mM)
NE
40 ± 21
158 ± 31
NE
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measure [3H]adenosine uptake. While the IC50 values for inhibition
of [3H]adenosine uptake by three purines were similar to WT
PvENT1 (Table 4) the amount of uptake at 15 min was 5e10-fold
lower than the amount of uptake into WT-expressing yeast. Thus,
the N329S mutant transported [3H]adenosine, but either the rate of
transport per transporter or the number of N329S transporters in
the plasma membrane was lower than for WT. Differences in the
media pH and composition in the uptake and growth assays did not
affect N329S function. The [3H]adenosine uptake experiments were
done at pH 7.4 whereas the growth media had a pH ~4.2. [3H]
adenosine uptake in 15 min for both WT- and N329S-expressing
yeast was comparable in PBS at pH 4.2 and 7.4, the absolute
amounts were different for WT and N329S (n ¼ 5, data not shown).
Furthermore, the amount of [3H]adenosine taken up in 15 min was
comparable whether the buffer was PBS or SDMmedia (n ¼ 4, datanot shown). Thus, neither a difference in the effect of media pH on
the N329S mutant or the media composition explains the failure of
N329S-expressing yeast to grow with adenosine as the sole purine
source.
We determined whether the PvENT1 non-synonymous SNP
mutations altered the sensitivity to the PfENT1 inhibitor com-
pounds (Fig. 3A). For most of the compounds, the PvENT1 SNPs had
IC50 values comparable to WT PvENT1 in the [3H]adenosine uptake
inhibition assays. For the D23E mutant, the IC50 values for com-
pounds 3, 6 and 7were ~3.5 fold higher thanWT (p < 0.05, data not
shown), but the mutant was more sensitive thanWT to compounds
1 and 4. The N329S mutant induced a 2.6 fold increase in the IC50 of
compound 2 relative toWT. No SNP caused a similar effect across all
nine compounds. The results demonstrated that the SNP mutations
do not confer resistance to the majority of the PfENT1 inhibitors
identiﬁed and characterized in our initial screen.
Fig. 3. Structures of nine PfENT1 inhibitors and the concentrationeresponse relationships for the effects on PvENT1. (A) PfENT1 inhibitors identiﬁed in a yeast-based HTS and
characterized in yeast and parasite based assays as described previously (Frame et al., 2015b). Structures of the nine compounds are labeled by their Rank Order # from the initial
screen. The nine compounds represent six distinct chemotypes. (B) Concentrationeresponse relationships for the effects of the nine PfENT1 inhibitors on [3H]adenosine uptake into
PvENT1-expressing yeast. CPM, counts per minute. Results are from one representative experiment.
Table 3
Efﬁcacy of PfENT1 inhibitors against PvENT1 using two assays of PvENT1 function. IC50 values for inhibition of [3H]adenosine uptake into or growth of PvENT1-expressing yeast
by nine PfENT1 inhibitors. IC50 values are represented as the mean ± SD from n  3 separate experiments. Compound numbers based on Rank Order# in HTS (Frame et al.,
2015b). Compound structures are in Fig. 3A. Data for IC50 values for compound efﬁcacy against PfENT1 in the [3H]adenosine uptake assay are shown for comparison.
Compound# PvENT1 IC50 in [3H]Adenosine uptake
assay (nM)
PfENT1 IC50 in [3H]Adenosine uptake
assay (nM)a
PvENT1 IC50 for growth inhibition of purine auxotrophic yeast in adenosine
containing media (nM)
1 1.8 ± 0.8 3.0 ± 1.3 63 ± 26
2 22.4 ± 11.8 10 ± 8.4 703 ± 178
3 2.6 ± 0.9 2.4 ± 1.5 77 ± 8
4 32.3 ± 19.9 13.7 ± 7.5 1170 ± 188
5 31.7 ± 7.6 22.7 ± 7.2 785 ± 390
6 9.5 ± 3.7 9.6 ± 7.4 396 ± 50
7 5.2 ± 2.6 10.9 ± 6.8 155 ± 26
13 7.5 ± 4.0 3.9 ± 1.6 159 ± 50
19 8.3 ± 0.9 38.4 ± 16.5 234 ± 41
a PfENT1 data from (Frame et al., 2015b).
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Multidrug-resistant malaria parasites have become more com-
mon. Thus it is imperative to develop new antimalarial compounds
that target novel aspects of parasite biology. Inhibition of the purine
import pathway(s) is one potential target for the development of
novel antimalarial drugs (Carter et al., 2001; Downie et al., 2006; El
Bissati et al., 2006; Riegelhaupt et al., 2010a; Frame et al., 2015b).
However, a major hurdle has been the difﬁculty in developing HTS
assays to identify inhibitors of equilibrative nucleoside trans-
porters. Recently, we described a yeast-based growth assay that we
used to screen a 64,500 compound library. We identiﬁed inhibitors
of PfENT1, the primary purine import pathway in P. falciparum
parasites (Frame et al., 2015b). Nine of the highest afﬁnity PfENT1
inhibitors, comprising six distinct chemotypes, kill P. falciparum
parasites in culture (Frame et al., 2015b). Because of the consider-
able geographical overlap in the distributions of P. falciparum and
P. vivax, to be effective, novel drugs should ideally target both
species. In the present work we have characterized the P. vivax
equilibrative nucleoside transporter homolog, PvENT1, in a yeast
expression system. We show that it has a similar, but distinct,
substrate proﬁle compared to PfENT1. Furthermore, the PfENT1
inhibitors that we identiﬁed previously (Frame et al., 2015b) are
highly efﬁcacious inhibitors of PvENT1. This implies that it may be
feasible to develop inhibitors of the primary malaria purine import
transporter as potential novel antimalarial drugs that will be
effective against both falciparum and vivax malaria.Despite 75% amino acid sequence identity between PfENT1 and
PvENT1, PvENT1 displays functional differences from PfENT1 in
terms of substrate interaction proﬁles. PvENT1 is more selective for
purines than for pyrimidines. Compared to PfENT1, the IC50 values
for inosine and guanosine were lower than for adenosine, a proﬁle
similar to the Leishmania donovani LdNT2 transporter (Carter et al.,
2000b). Inosine had the lowest IC50 for inhibition of [3H]uridine
uptake, followed by guanosine and adenosine/hypoxanthine. Hy-
poxanthine and adenosine are endogenous purine substrates for
PfENT1 (and for isolated P. falciparum parasites). PvENT1 had 4e5
fold lower IC50 values for hypoxanthine and adenosine, ~100 mM
and ~140 mM, respectively, than PfENT1, ~480 mM for hypoxanthine
and ~650 mM for adenosine (Riegelhaupt et al., 2010a). These dif-
ferences may relate to the fact that P. vivax parasites only infect
reticulocytes, immature erythrocytes, whereas P. falciparum para-
sites infect mature erythrocytes as well as reticulocytes. The cyto-
plasmic environment and purine composition is different in
immature vs mature erythrocytes (Srivastava et al., 2015). It re-
mains to be determined if the difference is a consequence of their
respective preference for immature versus mature erythrocytes.
Furthermore, it is unknown whether the differences in purine IC50
values for PvENT1 versus PfENT1 are physiologically signiﬁcant.
One of the important ﬁndings from this study was that the
PfENT1 inhibitors that we identiﬁed previously are also potent in-
hibitors of PvENT1 with IC50 values in the low nM range. In the
present study, we showed that the nine compounds inhibited [3H]
adenosine uptake into PvENT1-expressing yeast and inhibited
Fig. 4. Analysis of PvENT1-dependent growth of SNP mutations expressed in yeast. (A)
Equal number of mid-log phase PvENT1 WT and SNP mutant strain yeast cells were
serially diluted 5-fold and spotted onto adenine (1 mM; left) or adenosine (10 mM;
right) agar media plates. (B and C) Bioscreen analysis growth curves for WT and
PvENT1 SNP mutant strains grown in liquid culture media containing (B) 1 mM
adenine and (C) 10 mM adenosine as the sole purine source. OD600 measurements
were obtained at 15-min intervals (see Materials and Methods). Note in some places
the traces for the different mutants are overlapping.
Table 4
Purine IC50 values for inhibition of 3H-substrate uptake by yeast expressing PvENT1
containing mutations identiﬁed in P. vivax ﬁeld isolates with non-synonymous SNPs
in the pvent1 gene. [3H]uridine uptakewas used to assess PvENT1 activity. #Indicates
that the radiolabel used was [3H]adenosine, not [3H]uridine. *Signiﬁcantly different
thanWT (p < 0.05), unpaired Student t-test unequal variance. Values aremean ± SD.
IC50 values for inhibition of [3H]substrate uptake by the
indicated purine (mM)
SNP Hypoxanthine Inosine Adenosine
WT 141 ± 24# 5 ± 4# 167 ± 52
D23E 150 ± 164 123 ± 113 94 ± 93
M99I/Q367K 107 ± 13# 6 ± 2# 206 ± 28
Q178K 530 ± 110* 32 ± 5* 600 ± 270
L188M 1200 ± 780 130 ± 23* 190 ± 120
N329S 158 ± 18# 10 ± 4# 205 ± 31
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are not toxic to yeast at concentrations up to hundreds of micro-
molar (Frame et al., 2015b). Thus, at the sub-micromolar concen-
trations where the compounds inhibit adenosine-dependent
growth, it is likely due to inhibition of PvENT1-dependent adeno-
sine uptake. The efﬁcacy of the nine compounds in both assays is
consistent with their site of action being inhibition of PvENT1. The
differences in the IC50 values measured in the two assays is a
function of the fundamental differences in the assays and does not
represent a difference in the strength of the inhibitor's interaction
with PvENT1. The IC50 values in the growth experiments depend on
the level of PvENT1 expression and thus, the amount of excess
purine transport capacity relative to the purine requirements for
yeast cell growth and proliferation. Thus, the IC50 values in the
growth experiments do not directly reﬂect the afﬁnity of the in-
hibitors for PvENT1, but rather the fraction of expressed PvENT1
that must be inhibited to make purine uptake limit yeast cell
growth. In the inhibition of [3H]adenosine uptake assay, the
measured IC50 values are a direct measure of interaction between
the inhibitor and PvENT1.
Alternatively, the adenosine concentration is 1 mM in the
growth assay and only 50 nM in the [3H]adenosine uptake assay, in
the former case, ~10 times the adenosine IC50 and in the latter
~2000-fold lower. The difference may represent competition be-
tween adenosine and the inhibitor for an overlapping binding site.
Overall, our results provide strong evidence that the PfENT1 small
molecule inhibitors also block PvENT1, in many cases with higher
potency (Frame et al., 2015b). The ability of these nine compounds
to inhibit both PfENT1 and PvENT1 provides further support for the
hypothesis that malaria purine transporters are a reasonable target
for the development of novel antimalarial drugs.
In contrast to the efﬁcacy of the PfENT1 inhibitors against
PvENT1, hENT1 inhibitors had little or no efﬁcacy against PvENT1.
PvENT1 was not sensitive to NBMPR, an inosine analog where the
C6 oxygen is replaced with the more bulky S-nitrobenzyl moiety.
This result is in agreement with the NBMPR-insensitivity observed
for other protozoan ENTs (de Koning et al., 2005). Dipyridamole did
inhibit PvENT1 with a 40 mM IC50 but this is over 1000-fold higher
than its efﬁcacy against hENT1. The Plasmodium homologs are only
17% sequence identical to hENT1 so this result was not unexpected.
Since both hENT1 and the Plasmodium ENTs recognize purines with
similar afﬁnity, this suggests that dipyridamole binding afﬁnity
probably depends on residues in the transporter besides those
involved in purine recognition.
We investigated the impact of known non-synonymous PvENT1
SNPs identiﬁed in sequenced ﬁeld isolates. Growth of yeast
expressing ﬁve of the six SNPs with adenosine as the sole purine
source was similar to growth rates of yeast expressing WT PvENT1.
Wewere surprised that yeast expressing the N329S-PvENT1 variant
were unable to grow in adenosine, although they grew normally
with adenine as the sole purine source, because the IC50 values for
adenosine, inosine, and hypoxanthine inhibition of [3H]uridine
uptake for N329S-expressing yeast were similar to the IC50 values
obtained withWT-expressing yeast. We ruled out differences in the
media pH or composition as potential effects. It is most likely due to
a difference in N329S function or level of expression relative toWT.
Further experiments will be necessary to explain these results.
Some naturally occurring PfENT1 SNPs have functional effects
on purine uptake (e.g., F394L; ref. (Riegelhaupt et al., 2010b))
(Table 4). Given the small numbers of identiﬁed PvENT1 non-
synonymous SNPs and that these SNPs have similar afﬁnity for
the identiﬁed PfENT1 inhibitors, currently existing SNPs do not
represent a potential source of pre-existing resistance to the
inhibitors.
Most protozoan species have de novo pyrimidine synthesis
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Nevertheless, our experiments show that PvENT1 can bind to and
probably transport various pyrimidine compounds. In the case of
uridine, we showed that it is transported by PvENT1. Knowledge of
the PvENT1 pyrimidine binding proﬁle may be useful in designing
drugs that target the de novo pyrimidine biosynthetic pathway and
might use PvENT1 as a transport pathway for drug entry.
5. Conclusions
The parasite purine salvage pathway has been a target of various
potent antimalarial compounds (e.g., deoxycoformycin, immu-
cillins) (Webster et al., 1984; Kicska et al., 2002; Ting et al., 2005). In
this body of work, we have characterized the functional properties
of PvENT1, a potential antimalarial target. While PfENT1 and
PvENT1 share a high degree of amino acid sequence identity, dif-
ferences in amino acids in PvENT1 result in altered afﬁnities for
purine substrates. Nonetheless, PvENT1 (and the known non-
synonymous SNP variants) are inhibited by a new class of small
molecule inhibitors that target the P. falciparum purine importer
PfENT1. Development of these inhibitors as novel antimalarial
drugs may provide an additional arsenal of antimalarial com-
pounds that have no overlap with current chemotherapeutics.
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